Lactococcus lactis shows promise for T1DMOral administration of Lactococcus lactis-expressing heat shock protein 65 and tandemly repeated IA2P2 prevents type 1 diabetes in NOD mice.
We investigated the potential of Lactococcus lactis, a safe bacterial strain, to deliver protective proteins for preventing type 1 diabetes (T1DM) in NOD mice. Our study used two specially engineered strains that expressed a specific protein.
We found that oral administration of these Lactococcus lactis strains helped stop high blood sugar, enhanced glucose tolerance, and reduced inflammation in the pancreas. This occurred by suppressing certain auto-reactive T cells and encouraging healthy immune responses. Our results suggest that this method could effectively help prevent T1DM in these mice.
Read More
LA enhances Tacrolimus efficacy Supplementation Exerts a Synergistic Effect on Tacrolimus Efficacy by Modulating Th17/Treg Balance in Lupus-Prone Mice the SIGNR3 Pathway.
We investigated the effects of combining lactic acid (LA) with Tacrolimus (Tac) on treating lupus in mice. By administering both treatments, we observed an improvement in gut health and a balanced ratio of T cell subsets.
The combination therapy significantly decreased harmful autoantibody levels and improved kidney health. Additionally, it boosted regulatory T (Treg) cells while reducing T helper 17 (Th17) cells, ultimately enhancing the effectiveness of Tac for managing lupus-like conditions.
Read More
Probiotic shows promise for rheumatoid arthritisA single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis.
We assessed how Lactobacillus casei, a type of probiotic bacteria, impacted autoimmune responses in rats with rheumatoid arthritis. The treatment showed promise, significantly reducing joint swelling and preventing bone destruction by restoring the gut microbiome.
The analysis revealed that L. casei not only helped correct microbiome imbalances but also lowered inflammation indicators. Though these results are promising, further investigation is needed to confirm the effectiveness of probiotics in human arthritis treatment.
Read More
Synbiotics improve rheumatoid arthritis outcomesSynbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial.
We examined how synbiotic supplementation impacts patients with rheumatoid arthritis over 8 weeks. In our double-blind, placebo-controlled trial involving 54 participants, we found that those taking synbiotics experienced significant improvements. These included lower inflammation markers such as hs-CRP and better joint pain scores on the DAS-28 and VAS.
Additionally, improvements were noted in insulin resistance and oxidative stress markers, hinting at potential metabolic benefits. Overall, our findings suggest that synbiotic treatment could play a role in managing some aspects of rheumatoid arthritis effectively.
Read More
Probiotic IRT5 reduces diabetes effectsAmelioration of Autoimmune Diabetes of NOD Mice by Immunomodulating Probiotics.
We examined how a special probiotic mix, known as IRT5, affects autoimmune diabetes in non-obese diabetic (NOD) mice. Administered frequently over 36 weeks, this combination not only reduced diabetes incidence but also lowered insulitis scores and increased insulin-producing β-cell mass.
Additionally, IRT5 improved gut health and changed the makeup of immune cells in the pancreas and intestines. While some immune responses stayed the same, the shift towards more gut-focused regulatory T cells suggests it could be a promising treatment for type 1 diabetes.
Read More